PSR-Agility Wins Second Consecutive ROAR Award for Best Orphan Drug CRO
The PSR-Agility Orphan Drug Development partnership has for the second consecutive year been awarded “Best Orphan Drug Contract Research Organisation” in the Rare & Orphan Advocacy and Research (ROAR) Awards.
The ROAR Awards were announced during the 5th Annual World Orphan Drug Congress Europe, 12–14 November 2014, in Brussels, Belgium. The 2014 awards recognize those who have done outstanding work in the rare disease field, honour those who have made significant contributions to the development of the sector, and celebrate the great achievements made in the world of orphan drugs in the last year.
“Successively winning this award as the PSR-Agility Orphan Drug Development partnership is a clear appreciation by all stakeholders of our continued commitment in the rare disease community,” says Roger Legtenberg, CEO of PSR Orphan Experts. “Our efforts to provide crucial patient assistance by a range of services to lower the burden of rare disease patients in clinical trials, together with added infrastructure to be able to offer innovative patient recruitment solutions, have among others contributed considerably towards winning this award.”
“We’re thrilled that our commitment to innovating clinical development strategies for clients developing orphan drugs has been recognized consistently during our company’s first 2 years of partnership,” says Ellen Morgan, CEO of Agility. “Our vision for making a difference by dedicating ourselves to this specialty has become a reality.”
Orphan drugs present fundamentally different regulatory and operational challenges compared to their traditional counterparts. PSR-Agility Orphan Drug Development specializes in assisting companies to develop efficiencies and economies of scale to bring innovative new orphan products to market, thereby contributing to the IRDiRC 2020 goal to deliver 200 new therapies for rare diseases. Our staff are all highly engaged to the rare disease cause, by providing education, taking part in fundraising events and being involved in public-private partnerships. Building successful partnerships with all stakeholders, including patient organizations, industry and key opinion leaders, and actively collaborating with them, is of crucial importance.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance